Although prostate cancer (PCa) is the most commonly diagnosed cancer in men, most
patients do not die from the disease. Prostate specific antigen (PSA), the most widely used …

Since the introduction of serum prostate-specific antigen (PSA) screening 25 years ago,
prostate cancer diagnosis and management have been guided by this biomarker. Yet, PSA …

The introduction and widespread adoption of PSA has revolutionized the way prostate
cancer is diagnosed and treated. However, the use of PSA has also led to over-diagnosis …

INTRODUCTION: Due to its universal applicability for early detection and prediction of
cancer stage and disease recurrence, widespread implementation of serum-based prostate …

Background The use of biomarkers for prostate cancer screening, diagnosis and prognosis
has the potential to improve the clinical management of the patients. Owing to inherent …

The application of prostate-specific antigen (PSA) in prostate cancer (PC) screening,
diagnosis, and prognosis has improved the clinical management of PC patients. However …

Introduction: Prostate cancer is a common malignancy with highly variable clinical
presentation and outcomes. Diagnosis and management remain a challenge and at times …

Prostate specific antigen (PSA) is one of the best-known biomarkers for screening, diagnosis
and follow-up of patients for prostate cancer. Owing to several inherent limitations with PSA …

Prostate-specific antigen (PSA) is widely used as a biomarker in the detection of prostate
cancer and for decision making regarding treatment options, response to therapy, and …

Due to its significant applicability for early detection, risk prediction and follow-up evaluation,
prostate specific antigen (PSA) has revolutionized our ability to treat prostate cancer …